Exogenous FIX consumption, excluding invasive procedures
| Year . | Annualized FIX consumption, IU/y . | |||
|---|---|---|---|---|
| Participant . | Mean . | |||
| 1 . | 2 . | 3 . | N = 3 . | |
| Baseline | 223 429∗ | 261 186∗ | 434 000∗ | 306 205∗ |
| 1† | 0 | 0 | 1705 | 568.3 |
| 2 | 0 | 0 | 3400 | 1133.3 |
| 3 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 |
| 5 | 0 | 0 | 0 | 0 |
| Year . | Annualized FIX consumption, IU/y . | |||
|---|---|---|---|---|
| Participant . | Mean . | |||
| 1 . | 2 . | 3 . | N = 3 . | |
| Baseline | 223 429∗ | 261 186∗ | 434 000∗ | 306 205∗ |
| 1† | 0 | 0 | 1705 | 568.3 |
| 2 | 0 | 0 | 3400 | 1133.3 |
| 3 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 |
| 5 | 0 | 0 | 0 | 0 |
Data collected retrospectively 1 year before screening from medical records.
Postcontinuous FIX prophylaxis defined as a combination of 3 events: (1) study drug administered, (2) uncontaminated FIX activity (after treatment) has since been observed to be ≥5%, and (3) the patient has not used exogenous FIX for some continuous time period of at least 15 days after study drug administration.